The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).

The present disclosure provides fixed dose combinations of Drotaverine or a salt thereof and benzodiazepines, methods of preparing fixed dose combinations, and their use in treatment.

Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.

The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

The invention features compounds and pharmaceutical compositions having anti-inflammatory properties. Also provided are methods of using the compounds or compositions of the invention for treating an inflammatory disorder in a subject in need thereof.

A liquid concentrate formulated for dilution into a nutritional product is disclosed, as well as the resultant nutritional product, uses thereof, methods for the manufacture thereof, and methods for improving the cohesiveness of the nutritional product. The nutritional products have improved cohesiveness for promoting safer swallowing of food boluses for individuals having swallowing difficulties such as dysphagia. In a preferred embodiment, the nutritional product is prepared by diluting a liquid concentrate of one or more of a beta-glucan, a plant-extracted gum such as okra gum, or a plant-derived mucilage. Preferably, the resultant nutritional product has a shear viscosity greater than 200 mPas and up to about 2,000 mPas, preferably greater than 200 mPas and up to about 500 mPas, more preferably 250 mPas to about 450 mPas, most preferably 250 mPas to about 400 mPas, when measured at a shear rate of 50 s.sup.−1 at a temperature of 20° C.

The present invention provides, inter alia, compounds capable of inhibiting NF-κB. Pharmaceutical compositions containing and methods of using the compounds are also provided herein. Also provided are compositions, methods and kits for treating autoimmune diseases, including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, all comprising and/or utilizing the NF-κB inhibitors described herein.

The present invention relates to compositions, particularly baby food compositions, including living propionic acid-producing bacteria, preferably lactate-utilizing propionic acid-producing bacteria, their manufacture and use in the treatment of digestive diseases, particularly for treatment of infantile colic.

The present invention relates to compositions, particularly baby food compositions, including living propionic acid-producing bacteria, preferably lactate-utilizing propionic acid-producing bacteria, their manufacture and use in the treatment of digestive diseases, particularly for treatment of infantile colic.

The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.